0001104659-20-140307.txt : 20201229
0001104659-20-140307.hdr.sgml : 20201229
20201229215223
ACCESSION NUMBER: 0001104659-20-140307
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201222
FILED AS OF DATE: 20201229
DATE AS OF CHANGE: 20201229
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FRATTAROLI JOSEPH
CENTRAL INDEX KEY: 0001272668
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39676
FILM NUMBER: 201423916
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc.
CENTRAL INDEX KEY: 0001750149
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900
CITY: ATLANTA
STATE: GA
ZIP: 30339
BUSINESS PHONE: 678-392-3419
MAIL ADDRESS:
STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900
CITY: ATLANTA
STATE: GA
ZIP: 30339
4
1
tm2039455d1_form4.xml
FORM 4
X0306
4
2020-12-22
0
0001750149
Inhibikase Therapeutics, Inc.
IKT
0001272668
FRATTAROLI JOSEPH
3350 RIVERWOOD PARKWAY SE, SUITE 1900
ATLANTA
GA
30339
0
1
0
0
Chief Financial Officer
Common Stock
2020-12-28
4
C
0
44143
10.00
A
44143
I
By Flagship Consulting, Inc.
Stock Option (right to buy)
10.00
2020-12-22
4
A
0
100000
0
A
2030-12-22
Common Stock
100000
100000
D
Convertible Note
10.00
2020-12-28
4
C
0
441431.52
0
D
2020-12-28
2021-12-31
Common Stock
44143
0
I
By Flagship Consulting, Inc.
One-third of the option will vest and become exercisable on 12/22/2021, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of the month beginning January 1, 2022.
/s/ Milton H. Werner, attorney-in-fact
2020-12-29